Denali Therapeutics Inc. (DNLI) valuation

  1. Home
  2. Financials
  3. DNLI
  4. Valuation

Share price $19.20 · As of last filing 2026-03-31

Price-to-Earnings

P/E · Trailing Diluted
-6.67×
P/E history →

Price-to-Free-Cash-Flow

P/FCF · Trailing
-7.20×
P/FCF history →

Free-Cash-Flow Yield

FCF Yield · Trailing
-13.88%
FCF Yield history →

Enterprise-Value-to-EBITDA

EV/EBITDA · Trailing
-3.80×
EV/EBITDA history →

Price-to-Sales

P/S · Trailing
—
P/S history →

Price-to-Book

P/B · Latest filing
3.29×
P/B history →

What these ratios mean & how they're built: see the valuation ratios glossary on the Financials methodology page — per-ratio definitions and the exact us-gaap concepts behind each numerator and denominator.

Sources. Denominators come from SEC EDGAR XBRL filings for DNLI (CIK 0001714899); analyst growth forecasts come from analyst consensus. Filing-anchored figures are rendered server-side at the split-adjusted close on the latest reported period-end — so every ratio reconciles to the same filing as every other figure on this page — and the share price, six ratio cards, EPV gap, and reverse-DCF outputs above re-anchor on the most recent daily close in the browser when JavaScript is enabled. The "Full calculation trail" sections stay anchored to the period-end close so the line-by-line arithmetic still reconciles. Per-share denominators are split-adjusted to today's share count.

Related tickers

BATRA

ATLANTA BRAVES HOLDINGS, INC.

IBKR

INTERACTIVE BROKERS GROUP, INC.

RPC

Ridgepost Capital, Inc.